264 related articles for article (PubMed ID: 25491927)
21. Classics in Chemical Neuroscience: Xanomeline.
Bender AM; Jones CK; Lindsley CW
ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
[TBL] [Abstract][Full Text] [Related]
22. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells.
DeLapp N; Wu S; Belagaje R; Johnstone E; Little S; Shannon H; Bymaster F; Calligaro D; Mitch C; Whitesitt C; Ward J; Sheardown M; Fink-Jensen A; Jeppesen L; Thomsen C; Sauerberg P
Biochem Biophys Res Commun; 1998 Mar; 244(1):156-60. PubMed ID: 9514902
[TBL] [Abstract][Full Text] [Related]
23. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
[TBL] [Abstract][Full Text] [Related]
24. Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors.
Fang L; Jumpertz S; Zhang Y; Appenroth D; Fleck C; Mohr K; Tränkle C; Decker M
J Med Chem; 2010 Mar; 53(5):2094-103. PubMed ID: 20158205
[TBL] [Abstract][Full Text] [Related]
25. The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist.
Bartolomeo AC; Morris H; Buccafusco JJ; Kille N; Rosenzweig-Lipson S; Husbands MG; Sabb AL; Abou-Gharbia M; Moyer JA; Boast CA
J Pharmacol Exp Ther; 2000 Feb; 292(2):584-96. PubMed ID: 10640295
[TBL] [Abstract][Full Text] [Related]
26. Role of receptor protein and membrane lipids in xanomeline wash-resistant binding to muscarinic M1 receptors.
Jakubík J; Tucek S; El-Fakahany EE
J Pharmacol Exp Ther; 2004 Jan; 308(1):105-10. PubMed ID: 14569060
[TBL] [Abstract][Full Text] [Related]
27. Design and Synthesis of γ- and δ-Lactam M
Davoren JE; Garnsey M; Pettersen B; Brodney MA; Edgerton JR; Fortin JP; Grimwood S; Harris AR; Jenkinson S; Kenakin T; Lazzaro JT; Lee CW; Lotarski SM; Nottebaum L; O'Neil SV; Popiolek M; Ramsey S; Steyn SJ; Thorn CA; Zhang L; Webb D
J Med Chem; 2017 Aug; 60(15):6649-6663. PubMed ID: 28598634
[TBL] [Abstract][Full Text] [Related]
28. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease.
Sramek JJ; Hurley DJ; Wardle TS; Satterwhite JH; Hourani J; Dies F; Cutler NR
J Clin Pharmacol; 1995 Aug; 35(8):800-6. PubMed ID: 8522637
[TBL] [Abstract][Full Text] [Related]
29. Novel persistent activation of muscarinic M1 receptors by xanomeline.
Christopoulos A; El-Fakahany EE
Eur J Pharmacol; 1997 Sep; 334(1):R3-4. PubMed ID: 9346340
[TBL] [Abstract][Full Text] [Related]
30. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
[TBL] [Abstract][Full Text] [Related]
31. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM
Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
Christopoulos A; Parsons AM; El-Fakahany EE
J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
[TBL] [Abstract][Full Text] [Related]
33. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
[TBL] [Abstract][Full Text] [Related]
34. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).
Bymaster FP; Wong DT; Mitch CH; Ward JS; Calligaro DO; Schoepp DD; Shannon HE; Sheardown MJ; Olesen PH; Suzdak PD; Swedberg MD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):282-9. PubMed ID: 7909558
[TBL] [Abstract][Full Text] [Related]
35. Preclinical to Human Translational Pharmacology of the Novel M
Uslaner JM; Kuduk SD; Wittmann M; Lange HS; Fox SV; Min C; Pajkovic N; Harris D; Cilissen C; Mahon C; Mostoller K; Warrington S; Beshore DC
J Pharmacol Exp Ther; 2018 Jun; 365(3):556-566. PubMed ID: 29563325
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35).
Tsunekawa H; Noda Y; Mouri A; Yoneda F; Nabeshima T
Behav Brain Res; 2008 Jul; 190(2):224-32. PubMed ID: 18420288
[TBL] [Abstract][Full Text] [Related]
37. Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.
Lange HS; Vardigan JD; Cannon CE; Puri V; Henze DA; Uslaner JM
Neuropharmacology; 2021 Oct; 197():108754. PubMed ID: 34389398
[TBL] [Abstract][Full Text] [Related]
38. Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys.
Buccafusco JJ; Terry AV
J Mol Neurosci; 2004; 24(1):85-91. PubMed ID: 15314255
[TBL] [Abstract][Full Text] [Related]
39. The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action.
Martino G; Puma C; Yu XH; Gilbert AK; Coupal M; Markoglou N; McIntosh FS; Perkins MN; Laird JMA
Pain; 2011 Dec; 152(12):2852-2860. PubMed ID: 22018972
[TBL] [Abstract][Full Text] [Related]
40. Classical and atypical agonists activate M1 muscarinic acetylcholine receptors through common mechanisms.
Randáková A; Dolejší E; Rudajev V; Zimčík P; Doležal V; El-Fakahany EE; Jakubík J
Pharmacol Res; 2015 Jul; 97():27-39. PubMed ID: 25882246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
